Roivant Sciences Ltd. (87S.F)
| Previous Close | 10.09 |
| Open | 10.00 |
| Bid | 10.10 x N/A |
| Ask | 11.10 x N/A |
| Day's Range | 9.99 - 10.05 |
| 52 Week Range | 7.45 - 12.30 |
| Volume | |
| Avg. Volume | 16 |
| Market Cap | 8.554B |
| Beta (5Y Monthly) | 1.34 |
| PE Ratio (TTM) | 2.05 |
| EPS (TTM) | 4.90 |
| Earnings Date | Jun 26, 2024 - Jul 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireRoivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
Roivant’s board of directors has approved a share repurchase program for up to $1.5 billion of the company’s common shares, including an agreed repurchase of the entire Sumitomo Pharma stake for $648 millionSumitomo Pharma repurchase reduces shares outstanding by 9%In the Phase 2 NEPTUNE study of once-daily oral brepocitinib in non-infectious uveitis (NIU), the 45 mg results represent the best Treatment Failure rates observed to date among active NIU studies measuring this registrational endpoin
PR NewswireRoivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600
Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions.
Simply Wall St.Roivant Sciences Third Quarter 2024 Earnings: Beats Expectations
Roivant Sciences ( NASDAQ:ROIV ) Third Quarter 2024 Results Key Financial Results Revenue: US$37.1m (up 118% from 3Q...
